Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Radiology
Erschienen in: European Radiology 12/2011

01.12.2011 | Contrast Media

Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines

verfasst von: Fulvio Stacul, Aart J. van der Molen, Peter Reimer, Judith A. W. Webb, Henrik S. Thomsen, Sameh K. Morcos, Torsten Almén, Peter Aspelin, Marie-France Bellin, Olivier Clement, Gertraud Heinz-Peer, on behalf of the Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR)

Erschienen in: European Radiology | Ausgabe 12/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The Contrast Media Safety Committee (CMSC) of the European Society of Urogenital Radiology (ESUR) has updated its 1999 guidelines on contrast medium-induced nephropathy (CIN).

Areas covered

Topics reviewed include the definition of CIN, the choice of contrast medium, the prophylactic measures used to reduce the incidence of CIN, and the management of patients receiving metformin.
Key Points
• Definition, risk factors and prevention of contrast medium induced nephropathy are reviewed.
• CIN risk is lower with intravenous than intra-arterial iodinated contrast medium.
• eGFR of 45 ml/min/1.73 m 2 is CIN risk threshold for intravenous contrast medium.
• Hydration with either saline or sodium bicarbonate reduces CIN incidence.
• Patients with eGFR ≥60 ml/min/1.73 m 2 receiving contrast medium can continue metformin normally.
Fußnoten
Literatur
1.
Morcos SK, Thomsen HS, Webb JAW et al (1999) Contrast-media-induced nephrotoxicity: a consensus report. Eur Radiol 9:1602–1613PubMed
2.
Thomsen HS, Morcos SK, ESUR Contrast Media Safety Committee (1999) Contrast media and metformin: guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media. Eur Radiol 9:738–740PubMed
3.
4.
McCullough PA, Stacul F, Davidson C et al (2006) Overview. Am J Cardiol 98:2K–4K
5.
Molitoris BA, Levin A, Warnock DG et al (2007) Improving outcomes from acute kidney injury. J Am Soc Nephrol 18:1992–1994PubMed
6.
Molitoris BA, Levin A, Warnock DG et al (2007) Improving outcomes of acute kidney injury: report of an initiative. Nat Clin Pract Nephrol 3:439–442PubMed
7.
Mehta RL, Kellum JA, Shah SV et al (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31PubMed
8.
Weisbord SD, Chen H, Stone RA et al (2006) Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol 17:2871–2877PubMed
9.
Solomon RJ, Mehran R, Natarajan MK et al (2009) Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol 4:1162–1169PubMed
10.
Waikar SS, Bonventre JV (2009) Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol 20:672–679PubMed
11.
Thomsen HS, Morcos SK (2009) Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT—a pooled analysis of two randomized trials. Eur Radiol 19:891–897PubMed
12.
Reddan D, Laville M, Garovic VD (2009) Contrast-induced nephropathy and its prevention: what do we really know from evidence-based findings? J Nephrol 22:333–351PubMed
13.
Toprak O (2007) What is the best definition of contrast-induced nephropathy? Ren Fail 29:387–388PubMed
14.
Davidson CJ, Hlatky M, Morrris KG et al (1989) Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial. Ann Intern Med 110:119–124PubMed
15.
McCullough PA, Sandberg KR (2003) Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 4:53–59
16.
Newhouse JH, Kho D, Rao QA, Starren J (2008) Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am J Roentgenol 191:376–382PubMed
17.
Bruce RJ, Djamali A, Shinki K et al (2009) Background fluctuation of kidney function versus contrast-induced nephrotoxicity. AJR Am J Roentgenol 192:711–718PubMed
18.
Toprak O (2007) Risk markers for contrast-induced nephropathy. Am J Med Sci 334:283–290PubMed
19.
Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR) (2005) In which patients should serum creatinine be measured before iodinated contrast medium administration? Eur Radiol 15:749–754PubMed
20.
Bartholomew BA, Harjai KJ, Dukkipati S et al (2004) Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 93:1515–1519PubMed
21.
Brown JR, DeVries JT, Piper WD et al (2008) Serious renal dysfunction after percutaneous coronary interventions can be predicted. Am Heart J 155:260–266PubMed
22.
McCullough PA, Wolyn R, Rocher LL et al (1997) Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103:368–375PubMed
23.
Mehran R, Aymong ED, Nikolsky E et al (2004) A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44:1393–1399PubMed
24.
Rihal CS, Textor SC, Grill DE et al (2002) Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105:2259–2264PubMed
25.
Dangas G, Iakovou I, Nikolsky E et al (2005) Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 95:13–19PubMed
26.
Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263PubMed
27.
Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612PubMed
28.
Glassock RJ, Winearls C (2008) The global burden of chronic kidney disease: how valid are the estimates? Nephron Clin Pract 110:c39–c47PubMed
29.
Delanaye P, Cohen EP (2008) Formula-based estimates of the GFR: equations variable and uncertain. Nephron Clin Pract 110:c48–c54PubMed
30.
Parfrey PS, Griffiths SM, Barrett BJ et al (1989) Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. New Engl J Med 320:143–149PubMed
31.
Gruberg L, Mintz GS, Mehran R et al (2000) The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 36:1542–1548PubMed
32.
Marenzi G, Lauri G, Assanelli E et al (2004) Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 44:1780–1785PubMed
33.
Alamartine E, Phayphet M, Thibaudin D et al (2003) Contrast medium-induced acute renal failure and cholesterol embolism after radiological procedures: incidence, risk factors, and compliance with recommendations. Eur J Intern Med 14:426–431PubMed
34.
Morcos SK (2005) Prevention of contrast media induced nephrotoxicity after angiographic procedures. J Vasc Interv Radiol 16:13–23PubMed
35.
McCullough PA, Soman SS (2005) Contrast-induced nephropathy. Crit Care Clin 21:261–280PubMed
36.
Nikolsky E, Mehran R, Lasic Z et al (2005) Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int 67:706–713PubMed
37.
McCarthy CS, Becker JA (1992) Multiple myeloma and contrast media. Radiology 183:519–521PubMed
38.
Preda L, Agazzi A, Raimondi S et al (2011) Effect on renal function of an iso-osmolar contrast agent in patients with monoclonal gammopathies. Eur Radiol 21:63–69PubMed
39.
Katzberg RW, Lamba R (2009) Contrast-induced nephropathy after intravenous administration: fact or fiction? Radiol Clin North Am 47:789–800PubMed
40.
Weisbord SD, Mor MK, Resnick AL et al (2008) Incidence and outcomes of contrast-induced AKI following computed tomography. Clin J Am Soc Nephrol 3:1274–1281PubMed
41.
Kim SM, Cha R, Lee JP et al (2010) Incidence and outcomes of contrast-induced nephropathy after computed tomography in patients with CKD: a quality improvement report. Am J Kidney Dis 55:1018–1025PubMed
42.
Bauer C, Melamed ML, Hostetter TH (2008) Staging of chronic kidney disease: time for a course correction. J Am Soc Nephrol 19:844–846PubMed
43.
Glassock RJ (2009) Estimated glomerular filtration rate: time for a performance review? Kidney Int 75:1001–1003PubMed
44.
Abutaleb N (2007) Why we should sub-divide CKD stage 3 into early (3a) and late (3b) components. Nephrol Dial Transplant 22:2728–2729PubMed
45.
Barrett BJ, Carlisle EJ (1993) Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 188:171–178PubMed
46.
Aspelin P, Aubry P, Fransson SG et al (2003) Nephrotoxic effects in high-risk patients undergoing angiography. New Engl J Med 348:491–499PubMed
47.
Jo SH, Youn TJ, Koo BK et al (2006) Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol 48:924–930PubMed
48.
Nie B, Cheng WJ, Li YF et al (2008) A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention. Catheter Cardiovasc Interv 72:958–965PubMed
49.
Rudnick MR, Davidson C, Laskey W et al (2008) Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. Am Heart J 156:776–782PubMed
50.
Solomon RJ, Natarajan MK, Doucet S et al (2007) Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 115:3189–3196PubMed
51.
Wessely R, Koppara T, Bradaric C et al (2009) Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2:430–437PubMed
52.
Laskey W, Aspelin P, Davidson C et al (2009) Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures. Am Heart J 158:822–828PubMed
53.
Briguori C, Colombo A, Airoldi F et al (2005) Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int 68:2250–2255PubMed
54.
Chalmers N, Jackson RW (1999) Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 72:701–703PubMed
55.
Hardiek KJ, Katholi RE, Robbs RS, Katholi CE (2008) Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography. J Diabetes Complications 22:171–177PubMed
56.
Juergens CP, Winter JP, Nguyen-Do P et al (2009) Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial. Intern Med J 39:25–31PubMed
57.
Mehran R, Nikolsky E, Kirtane AJ et al (2009) Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study. JACC Cardiovasc Interv 2:415–421PubMed
58.
Nguyen SA, Suranyi P, Ravenel JG et al (2008) Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function. Radiology 248:97–105PubMed
59.
Thomsen HS, Morcos SK, Erley CM et al (2008) The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol 43:170–178PubMed
60.
Barrett BJ, Katzberg RW, Thomsen HS et al (2006) Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed-tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol 41:815–821PubMed
61.
Carraro M, Malalan F, Antonione R et al (1998) Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind randomized clinical trial. Eur Radiol 8:144–147PubMed
62.
Kuhn MJ, Chen N, Sahani DV et al (2008) The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low or isoosmolar contrast agent exposure. AJR Am J Roentgenol 191:151–157PubMed
63.
Heinrich MC, Häberle L, Müller V et al (2009) Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology 250:68–86PubMed
64.
Reed M, Meier P, Tamhane UU et al (2009) The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv 2:645–654PubMed
65.
McCullough PA, Bertrand ME, Brinker JA, Stacul F (2006) A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 48:692–699PubMed
66.
Laskey WK, Jenkins C, Selzer F et al (2007) Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol 50:584–590PubMed
67.
Nyman U, Biörk J, Aspelin P, Marenzi G (2008) Contrast medium dose-to-GFR ratio: a measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention. Acta Radiol 49:658–667PubMed
68.
Manske CL, Sprafka JM, Strony JT, Wang Y (1990) Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 89:615–620PubMed
69.
Ellis JH, Cohan RH (2009) Prevention of contrast induced nephropathy: an overview. Radiol Clin N Am 47:801–811PubMed
70.
Stacul F, Adam A, Becker CR et al (2006) Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 98:59K–77KPubMed
71.
Trivedi HS, Moore H, Nasr S et al (2003) A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 93:C29–C34PubMed
72.
Dussol B, Morange S, Loundoun A et al (2006) A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant 21:2120–2126PubMed
73.
Taylor AJ, Hotchkiss D, Morse RW, McCabe J (1998) PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 114:1570–1574PubMed
74.
Mueller C, Buerkle G, Buettner HJ et al (2002) Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 162:329–336PubMed
75.
Bader BD, Berger ED, Heede MB et al (2004) What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol 62:1–7PubMed
76.
Krasuski RA, Beard BM, Geoghagan JD et al (2003) Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. J Invasive Cardiol 15:699–702PubMed
77.
Joannidis M, Schmid M, Wiedermann CJ (2008) Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis. Wien Klin Wochenschr 120:742–748PubMed
78.
Merten GJ, Burgess WP, Gray LV et al (2004) Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291:2328–2334PubMed
79.
Brar SS, Hiremath S, Dangas G et al (2009) Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol 4:1584–1592PubMed
80.
Hogan SE, L’allier P, Chetcuti S et al (2008) Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis. Am Heart J 156:414–421PubMed
81.
Meier P, Ko DT, Tamura A et al (2009) Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis. BMC Med 7:23PubMed
82.
Navaneethan SD, Singh S, Appasamy S et al (2009) Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis 53:617–627PubMed
83.
Weisbord SD, Palevsky PM (2008) Prevention of contrast-induced nephropathy with volume expansion. Clin J Am Soc Nephrol 3:273–280PubMed
84.
Biondi-Zoccai GG, Lotrionte M, Abbate A et al (2006) Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. BMJ 332:202–209PubMed
85.
Trivedi H, Nadella R, Szabo A (2010) Hydration with sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials. Clin Nephrol 74:288–296PubMed
86.
Tamura A, Goto Y, Miyamoto K et al (2009) Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure. Am J Cardiol 104:921–925PubMed
87.
Briguori C, Colombo A, Airoldi F et al (2004) N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 44:762–765PubMed
88.
Majumdar SR, Kjellstrand CM, Tymchak WJ et al (2009) Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis 54:602–609PubMed
89.
Ng TM, Shurmur SW, SIlver M et al (2006) Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN). Int J Cardiol 109:322–328PubMed
90.
Stone GW, McCullough PA, Tumlin JA et al (2003) Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 290:2284–2291PubMed
91.
Attallah N, Yassine L, Musial J et al (2004) The potential role of statins in contrast nephropathy. Clin Nephrol 62:273–278PubMed
92.
Boscheri A, Weinbrenner C, Botzek B et al (2007) Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction. Clin Nephrol 68:279–286PubMed
93.
Briguori C, Airoldi F, D’Andrea D et al (2007) Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 115:1211–1217PubMed
94.
Ix JH, McCulloch CE, Chertow GM (2004) Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant 19:2747–2753PubMed
95.
Huber W, Eckel F, Hennig M et al (2006) Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. Radiology 239:793–804PubMed
96.
Jo SH, Koo BK, Park JS et al (2008) Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial—a randomized controlled study. Am Heart J 155:499.e1–499.e8
97.
Kelly AM, Dwamena B, Cronin P et al (2008) Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 148:284–294PubMed
98.
Khanal S, Attallah N, Smith DE et al (2005) Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 118:843–849PubMed
99.
Patti G, Nusca A, Chello M et al (2008) Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 101:279–285PubMed
100.
Spargias K, Adreanides E, Demerouti E et al (2009) Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 120:1793–1799PubMed
101.
Spargias K, Alexopoulos E, Kyrzopoulos S et al (2004) Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 110:2837–2842PubMed
102.
Tepel M, van der Giet M, Schwarzfeld C et al (2000) Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. New Engl J Med 343:180–184PubMed
103.
Azmus AD, Gottschall C, Manica A et al (2005) Effectiveness of acetylcysteine in prevention of contrast nephropathy. J Invasive Cardiol 17:80–84PubMed
104.
Briguori C, Manganelli F, Scarpato P et al (2002) Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 40:298–303PubMed
105.
Briguori C, Colombo A, Violante A et al (2004) Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 25:206–211PubMed
106.
Kay J, Chow WH, Chan TM et al (2003) Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 289:553–558PubMed
107.
Marenzi G, Assanelli E, Marana I et al (2006) N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. New Engl J Med 354:2773–2782PubMed
108.
Webb JG, Pate GE, Humphries KH et al (2004) A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 148:422–429PubMed
109.
Trivedi H, Daram S, Szabo A et al (2009) High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med 122:874.e9–874.e15
110.
Fishbane S (2008) N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol 3:281–287PubMed
111.
Gonzales DA, Norsworthy KJ, Kern SJ et al (2007) A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med 5:32PubMed
112.
Pannu N, Wiebe N, Tonelli M (2006) Prophylaxis strategies for contrast-induced nephropathy. JAMA 295:2765–2779PubMed
113.
Sinert R, Doty CI (2007) Evidence-based emergency medicine review. Prevention of contrast-induced nephropathy in the emergency department. Ann Emerg Med 50:335–345PubMed
114.
Zagler A, Azadpour M, Mercado C, Hennekens CH (2006) N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J 151:140–145PubMed
115.
Bagshaw SM, McAlister FA, Manns BJ, Ghali WA (2006) Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med 166:161–166PubMed
116.
Van Praet JT, De Vriese AS (2007) Prevention of contrast-induced nephropathy: a critical review. Curr Opin Nephrol Hypertens 16:336–347PubMed
117.
Vaitkus PT, Brar C (2007) N-acetylcysteine in the prevention of contrast-induced nephropathy: publication bias perpetuated by meta-analyses. Am Heart J 153:275–280PubMed
118.
Hoffmann U, Fischereder M, Krueger B et al (2004) The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 15:407–410PubMed
119.
Poletti PA, Saudan P, Platon A et al (2007) I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol 189:687–692PubMed
120.
Haase M, Haase-Fielitz A, Ratnaike S et al (2008) N-Acetylcysteine does not artifactually lower plasma creatinine concentration. Nephrol Dial Transplant 23:1581–1587PubMed
121.
Morcos SK, Thomsen HS, Webb JA et al (2002) Dialysis and contrast media. Eur Radiol 12:3026–3030PubMed
122.
Marenzi G, Lauri G, Campodonico J et al (2006) Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 119:155–162PubMed
123.
Marenzi G, Marana I, Lauri G et al (2003) The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. New Engl J Med 349:1333–1340PubMed
124.
Naughton CA (2008) Drug-induced nephrotoxicity. Am Fam Physician 78:743–750PubMed
125.
Pannu N, Nadim MK (2008) An overview of drug-induced acute kidney injury. Crit Care Med 36(4 Suppl):S216–S223PubMed
126.
Fishman EK, Reddan D (2008) What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography. Acta Radiol 49:310–320PubMed
127.
Reddan D, Fishman EK (2008) Radiologists’ knowledge and perceptions of the impact of contrast-induced nephropathy and its risk factors when performing computed tomography examinations: a survey of European radiologists. Eur J Radiol 66:235–245PubMed
128.
Briguori C, Colombo A, Airoldi F et al (2006) Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheter Cardiovasc Interv 67:175–180PubMed
129.
Elmsthåhl B, Nyman U, Leander P et al (2004) Gadolinium contrast media are more nephrotoxic than a low osmolar iodine medium employing doses with equal X-ray attenuation in renal arteriography: an experimental study in pigs. Acad Radiol 11:1219–1228
130.
Erley CM, Bader BD, Berger ED et al (2004) Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients. Nephrol Dial Transplant 19:2526–2531PubMed
131.
Thomsen HS, Almèn T, Morcos SK et al (2002) Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 12:2600–2605PubMed
132.
Arsenault TM, King BF, Marsh JW Jr et al (1996) Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: retrospective analysis of an initial experience. Mayo Clin Proc 71:1150–1154PubMed
133.
Zhang HL, Ersoy H, Prince MR (2006) Effects of gadopentetate dimeglumine and gadodiamide on serum calcium, magnesium, and creatinine measurements. J Magn Reson Imag 23:383–387
134.
Hoffmann U, Fischereder M, Reil A et al (2005) Renal effects of gadopentetate dimeglumine in patients with normal and impaired renal function. Eur J Med Res 10:149–154PubMed
135.
Prince MR, Arnoldus C, Frisoli JK (1996) Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imag 6:162–166
136.
Tombach B, Bremer C, Reimer P et al (2001) Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology 218:651–657PubMed
137.
Sam AD II, Morasch MD, Collins J et al (2003) Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 38:313–318PubMed
138.
Ergun I, Keven K, Uruc I et al (2006) The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant 21:697–700PubMed
139.
Akgun H, Gonlusen G, Cartwright J et al (2006) Are gadolinium-based contrast media nephrotoxic? A renal biopsy study. Arch Pathol Lab Med 130:1354–1357PubMed
140.
Thomsen HS (2004) Gadolinium-based contrast media may be nephrotoxic even at approved doses. Eur Radiol 14:1654–1656PubMed
141.
Bolen S, Feldman L, Vassy J et al (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes. Ann Intern Med 147:386–399PubMed
142.
143.
Bailey CJ, Turner RC (1996) Metformin. New Engl J Med 334:574–579PubMed
144.
145.
Stang M, Wysowski DK, Butler-Jones D (1999) Incidence of lactic acidosis in metformin users. Diabetes Care 22:925–927PubMed
146.
Salpeter S, Greyber E, Pasternak G, Salpeter EE (2010) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev CD002967
147.
Cryer DR, Nicholas SP, Henry DH et al (2005) Comparative outcomes study of metformin intervention versus conventional approach the COSMIC approach study. Diabetes Care 28:539–543PubMed
148.
Sambol NC, Chiang J, Lin ET et al (1995) Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 35:1094–1102PubMed
149.
Sirtori CR, Pasik C (1994) Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res 30:187–228PubMed
150.
151.
Holstein A, Stumvoll M (2005) Contraindications can damage your health—is metformin a case in point? Diabetologia 48:2454–2459PubMed
152.
Shaw JS, Wilmot RL, Kilpatrick ES (2007) Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 24:1160–1163PubMed
153.
Warren RE, Strachan MWJ, Wild S, McKnight JA (2007) Introducing glomerular filtration rate (eGFR) into clinical practice in the UK: implications for the use of metformin. Diabet Med 24:494–497PubMed
154.
McCullough PA, Stacul F, Becker CR et al (2006) Contrast-Induced Nephropathy (CIN) Consensus Working Panel: executive summary. Rev Cardiovasc Med 7:177–197PubMed
155.
Rudnick MR, Goldfarb S, Wexler L et al (1995) Nephrotoxicity of ionic and non-ionic contrast media in 1196 patients: a randomised trial. Kidney Int 47:254–261PubMed
156.
Goergen SK, Rumbold G, Compton G, Harris C (2010) Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology 254:261–269PubMed
157.
Thomsen HS, Morcos SK, Almen T et al (2010) Metformin and contrast media. (Letter) Radiology 256:672–673PubMed
158.
Gupta R (2002) Use of contrast agents in patients receiving metformin. (Letter) Radiology 225:311–312PubMed
159.
Bettman MA (2002) Use of intravenous contrast agents in patients receiving metformin. (Letter) Radiology 225:312
Metadaten
Titel
Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines
verfasst von
Fulvio Stacul
Aart J. van der Molen
Peter Reimer
Judith A. W. Webb
Henrik S. Thomsen
Sameh K. Morcos
Torsten Almén
Peter Aspelin
Marie-France Bellin
Olivier Clement
Gertraud Heinz-Peer
on behalf of the Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR)
Publikationsdatum
01.12.2011
Verlag
Springer-Verlag
Erschienen in
European Radiology / Ausgabe 12/2011
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-011-2225-0

Weitere Artikel der Ausgabe 12/2011

European Radiology 12/2011 Zur Ausgabe

Vascular-Interventional

Radio-opaque ethylcellulose-ethanol is a safe and efficient sclerosing agent for venous malformations

Neuro

Trigeminal neuralgia: Assessment with T2 VISTA and FLAIR VISTA fusion imaging

Cardiac

Heart and liver T2* assessment for iron overload using different software programs

Cardiac

Accuracy and variability of right ventricular volumes and mass assessed by dual-source computed tomography: influence of slice orientation in comparison to magnetic resonance imaging

Neuro

Macromolecule content influences proton diffusibility in gliomas

Head and Neck

MR-Imaging of teeth and periodontal apparatus: an experimental study comparing high-resolution MRI with MDCT and CBCT

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

S3-Leitlinie zu Pankreaskrebs aktualisiert

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

13.04.2024 | Klinik aktuell | Kongressbericht | Nachrichten

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

08.04.2024 | Andrologie | Nachrichten

Wie toxische Männlichkeit der Gesundheit von Männern schadet
weitere anzeigen

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen